[1] Tang H,Liang Y,Anders RA,et al.PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression[J].Clin Invest,2018,128(2):580-588.
[2] Bakdash G,Buschow SI,Gorris M,et al.Expansion of a BDCA1+CD14+ myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines[J].Cancer Res,2016,76(15):4332-4346.
[3] Gordon SR,Maute RL,Dulken BW,et al.PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity[J].Nature,2017,545(7655):495-499.
[4] Thyagarajan A,Alshehri M,Miller K,et al.Myeloid-derived suppressor cells and pancreatic cancer:implications in novel therapeutic approaches[J].Cancers,2019,11(11):1627.
[5] Krishnamoorthy M,Gerhardt L,Maleki Vareki S.Immunosuppressive effects of myeloid-derived suppressor cells in cancer and immunotherapy[J].Cell,2021,10(5):1170.
[6] Boison D,Yegutkin GG.Adenosine metabolism:emerging concepts for cancer therapy[J].Cancer Cell,2019,36(6):582-596.
[7] Hugo W,Zaretsky JM,Sun L,et al.Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma[J].Cell,2016,165(1):35-44.
[8] Lamano JB,Lamano JB,Li YD,et al.Glioblastoma-derived IL-6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth[J].Clin Cancer Res,2019,25(12),3643-3657.
[9] Tsukamoto H,Fujieda K,Miyashita A,et al.Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment[J].Cancer Res,2018,78(17):5011-5022.
[10] Fukumura D,Kloepper J,Amoozgar Z,et al.Enhancing cancer immunotherapy using antiangiogenics:opportunities and challenges[J].Nat Rev Clin Oncol,2018,15(5):325-340.
[11] Kim JM,Chen DS.Immune escape to PD-L1/PD-1 blockade:seven steps to success (or failure)[J].Ann Oncol,2016,27(8):1492-1504.
[12] Hezaveh K,Shinde RS,Klotgen A,et al.Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity[J].Immunity,2022,55(2):324-340.
[13] Mitchell TC,Hamid O,Smith DC,et al.Epacadostat plus pembrolizumab in patients with advanced solid tumors:phase I results from a multicenter,open-label phase I/II trial (ECHO-202/KEYNOTE-037)[J].Clin Oncol,2018,36(32):3223-3230.
[14] Liu M,Sun Q,Wei F,et al.Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors[J].Cancer Biol Med,2020,17(3):626-639.
[15] Zhang W,Liu Y,Yan Z,et al.IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma[J].Immunother Cancer,2020,8(1):285.
[16] Wang TT,Zhao YL,Peng LS,et al.Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway[J].Gut,2017,66(11):1900-1911.
[17] Fleming V,Hu X,Weller C,et al.Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling[J].Cancer Res,2019,79(18):4715-4728. |
2023, Vol. 29 
